William Blair Issues Positive Outlook for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.50) per share for the quarter, up from their previous forecast of ($0.51). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and FY2026 earnings at ($2.05) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright raised their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Guggenheim reiterated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Robert W. Baird decreased their target price on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Finally, Truist Financial began coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price target on the stock. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $19.63.

Larimar Therapeutics Price Performance

LRMR opened at $2.97 on Monday. The stock's 50 day simple moving average is $2.36 and its 200 day simple moving average is $4.20. The firm has a market cap of $190.16 million, a price-to-earnings ratio of -2.58 and a beta of 0.91. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

Institutional Trading of Larimar Therapeutics

Several large investors have recently modified their holdings of LRMR. BNP Paribas Financial Markets bought a new position in shares of Larimar Therapeutics in the 4th quarter worth approximately $25,000. Virtu Financial LLC bought a new position in Larimar Therapeutics in the third quarter worth approximately $71,000. Algert Global LLC purchased a new position in shares of Larimar Therapeutics during the 4th quarter worth $47,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Larimar Therapeutics during the 4th quarter valued at $52,000. Finally, Graham Capital Management L.P. purchased a new stake in shares of Larimar Therapeutics in the 4th quarter worth $54,000. Institutional investors own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.